News >

Frontline Brentuximab Vedotin Generates 76% Complete Remission Rate in DLBCL

Laura Panjwani
Published: Tuesday, Dec 22, 2015

Christopher Yasenchak, MD

Christopher Yasenchak, MD

Adding brentuximab vedotin (Adcetris) to frontline R-CHOP produced a greater than 80% response rate—including complete remissions in three-fourths of patients—as a treatment for CD30+ diffuse large B-cell lymphoma (DLBCL), according to updated interim data from an ongoing phase II clinical trial recently presented at the 2015 ASH Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication